Teva announces new findings highlighting potential of proair® digihaler® (albuterol sulfate) inhalation powder to address asthma treatment challenges

Tel aviv, israel & parsippany, n.j.--(business wire)--teva pharmaceuticals, a u.s. affiliate of teva pharmaceutical industries ltd. (nyse and tase: teva), announced new study findings based on newly established clinical thresholds on short-acting beta agonist (saba) use that highlight real-world saba usage among patients with asthma in the u.s. and the potential for proair® digihaler® (albuterol sulfate) inhalation powder, a digital inhaler, to help inform treatment discussions and decisions. t
TEVA Ratings Summary
TEVA Quant Ranking